Nexalin Technology, Inc. (NXL) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US65345B2016
Nexalin Technology, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 301,647.00 USD |
| Gross profit | 240,274.00 USD |
| Operating income | -8.39 m USD |
| EBIT | -8.23 m USD |
| Net income | -8.22 m USD |
| Diluted EPS – continuing operations | -0.50 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
More stocks
- FibroBiologics, Inc. (FBLG)
- MUSTANG BIO, INC. (MBIO)
- TOFUTTI BRANDS INC (TOFB)
- OMNIQ Corp. (OMQS)
- Propanc Biopharma, Inc. (PPCB)
- Sunshine Biopharma Inc. (SBFM)
- Atacama Resources International, Inc. (ACRL)
- KUSTOM ENTERTAINMENT, INC. (KUST)
- Tianci International, Inc. (CIIT)
- HCW Biologics Inc. (HCWB)
- BioRestorative Therapies, Inc. (BRTX)
- NEXTNRG, INC. (NXXT)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.